After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Dyno Therapeutics has formed a new research partnership with Roche, focusing on the development of next-generation ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting ...

New strategic partnership leverages the power of Dyno’s platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...